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Five neurodegenerative diseases are caused by ex- 
panding CAG triplet repeats coding for polyglutamine. 
They all involve loss of selected populations of neurons, 
usually in adulthood. How the genetic lesions cause pro- 
gressive neuronal degeneration is unknown. Unraveling 
the pathogenesis of these disorders will help elucidate 
pathways of neuronal cell death. 
Triplet repeat disorders involve the recently identified 
phenomenon of unstable DNA, in which repeating units 
of 3 nucleotides uch as CAG expand during vertical trans- 
mission and cause disease (La Spada et al., 1994). They 
can be divided into two types. The first type (Figure 1) 
involves expanding CAG repeats coding for polygluta- 
mine. The normal length of the repeat is from 6 or 7 to about 
30, and the disease is present when the repeat expands to 
35-40 or more. Except for the androgen receptor of spinal 
and bulbar muscular atrophy (SBMA), none of the caus- 
ative genes has a known function or substantial homology 
with any known gene in the database. 
In the second type of disease (Table 1), triplet repeats 
such as CTG or CCG are present in mRNA outside the 
open reading frame (La Spada et al., 1994; Ross et al., 
1993). 
In all of the glutamine repeat diseases, there is loss of 
neurons with gliosis, but without deposition of extracellular 
material or intracellular inclusion bodies. Though the ex- 
pression patterns of the causative genes are widespread, 
the disorders involve loss of neurons within specific re- 
gions of the brain and spinal cord (Figure 1). It is possible 
that the glutamine repeat diseases share similar mecha- 
nisms of pathogenesis. 
Glutamine Repeat Diseases and Causative Genes 
Huntington's disease (HD) is the most common glutamine 
repeat disease. It is an autosomal dominant neurodegen- 
erative disorder characterized by abnormal movements 
including chorea, dementia, and emotional disorders. The 
pathology is notable for selective neuronal vulnerability 
of medium spiny projection neurons in the caudate and 
putamen. After a long search, the HD gene was identified 
and found to have an expanding CAG repeat (Huntington's 
Disease Collaborative Research Group, 1993). The mRNA 
contains a long open reading frame coding for a predicted 
protein of 348 kDa. Immediately adjacent to the glutamine 
repeat, there are two proline repeats interrupted by a pro- 
line-rich region. The protein product of the HD gene (hun- 
tingtin), like the mRNA, has a widespread expression in 
both the brain and the periphery (Sharp et al., 1995; Trot- 
tier et al., 1995). Within the brain, it is predominantly neu- 
ronal with no enrichment in the basal ganglia. It is present 
in cell bodies and dendrites and appears enriched in neu- 
ronal terminals, possibly associated with vessicles or mi- 
crotubules (DiFiglia et al., 1995; Gutekunst et al., 1995). 
Dentato-Rubral and Pallido-Luysian Atrophy (DRPLA or 
Smith's Disease) is a rare neurodegenerative disorder 
whose clinical features for adult onset cases are similar 
to those of HD. DRPLA was the first triplet repeat disease- 
causing gene (CTG-B37 or atrophin-1) to be cloned by 
screening for triplet repeats directly from cDNA libraries 
(Li et al., 1993). The predicted 120 kDa protein has a gluta- 
mine repeat, a proline repeat, and a region of alternating 
acidic and basic amino acids (Nagafuchi et al., 1994; Mar- 
golis et al., 1995). The protein product of the DRPLA gene 
has recently been identified and migrates at 190 kDa, 
slower than expected (Yazawa et al., 1995). Immunocyto- 
chemical data suggest a cytoplasmic distribution densest 
in the perinuclear egion but also present in proximal den- 
drites of neurons. 
Spinal cerebellar ataxia type 3 (SCA3 or Machado- 
Joseph Disease [MJD]) is a member of a class of diseases 
with related phenotypes and overlapping regions of neu- 
ronal degeneration. MJD presents with cerebellar ataxia, 
dystonia or rigidity, ophthalmoplegia, and sometimes 
bulging eyes. The causative gene for SCA3 was also iden- 
tified by direct screening of human brain cDNA libraries 
for triplet repeats (Kawaguchi et al., 1994). The gene is 
widely expressed; its protein product has not yet been 
identified. 
Spinal cerebellar ataxia type 1 (SCA1) is a progressive 
neurodegenerative disorder characterized by ataxia, dys- 
arthria, ophthalmoparesis, and bulbar motor weakness. 
The gene for SCA1, termed ataxin-1, was identified by 
positional cloning and screening of YACs for triplet repeats 
(Banff et al., 1994). The ataxin-1 protein has also recently 
been identified using antibodies (Servadio et al., 1995). 
Immunocytochemical data suggest both cytoplasmic and 
nuclear localization with a widespread distribution. 
SBMA is a rare late-onset form of motor neuron degener- 
ation. Patients often have signs of androgen insensitivity, 
including gynecomastia and testicular atrophy. The af- 
fected gene product, the androgen receptor (La Spada et 
al., 1991), is a member of a class of ligand-binding intracel- 
lular steroid receptors that can translocate to the nucleus 
to activate gene transcription via a zinc finger DNA-binding 
domain. While the expression of the androgen receptor 
mRNA is rather widespread, high levels of functional an- 
drogen-binding activity appear to be more restricted, in- 
cluding in spinal motor neurons. 
Glutamine Repeats 
The functions of glutamine repeats in proteins are un- 
known. CAG repeats were originally identified in Drosoph- 
ila, where they are found in many genes involved in regula- 
tion of development and neu rogenesis. Glutamine repeats 
are far more common than repeats of any other amino 
acid (Green and Wang, 1994). However, the length of the 
repeats is poorly conserved in homologous genes from 
different species. For example, the mouse HD gene en- 
codes only seven repeats. The glutamine repeat in the rat 
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Figure 1. GlutamLne Repeat Diseases 
The left side shows a schematic diagram of the major sites of neuronal loss in each disease. Dark red indicates severe or selective neuronal loss; 
half-tone red indicates moderate or variable cell loss. The circles in the cerebellar cortex represent Purkinje cells. The right side shows a schematic 
of the open reading frame of each causative gene. The glutamine repeat expansion is shown in red, with the approximate number of repeats in 
controls and in patients. AH, anterior horn; Cer, cerebellar cortex; C/P, caudate/putamen; Ctx, cerebral cortex; DN, dentate nucleus; GP, globus 
pallidus; LCN, lateral cuneate nucleus; PN, pontine nucleus; RN, red nucleus; SN, substantia nigra; STN, subthalamic nucleus; VL, ventrolateral 
thalamic nucleus; V, VI, VII, and XII, cranial motor nuclei. 
homolog of atrophin-1 has only 5 glutamines fol lowed by 
glutamine alternating with proline 4 times. 
Glutamine-rich regions have been described in the fac- 
tor interaction domain of several transcription factors. Al- 
though it is unclear whether glutamine repeats generally 
function like glutamine-rich regions, the expanding gluta- 
mine repeat in the androgen receptor is in a region thought 
to be important for interaction with other cell type-specif ic 
transcription factors (Adler et al., 1992). Lengthening the 
repeat may alter transactivation. Thus, glutamine repeats 
may function as protein-protein interaction motifs. 
Disease Pathogenesis 
How do these proteins cause disease? Is it due to loss of 
a protein's normal function or to a gain of function? The 
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Table 1. Type 2 Triplet Repeat Diseases 
Disease Gene Expanded Triplet Translation 
Fragile X syndrome, type A (FraX-A) FMR1 CCG x >200 5'-Untranslated 
Fragile X syndrome, type E (FraX-E) ? CCG x >200 ? Untranslated 
Myotonic dystrophy or dystrophia myotonica (DM) Myotonin protein kinase (DMK) CTG x >200 3'-Untranslated 
Jacobsen syndrome with Fral 1B CBL2 proto-oncogene CCG 5'-Untranslated 
recent development of an HD gene knockout (Duyao et 
al., 1995; Nasir et al., 1995; Zeitlin et al., 1995) provides an 
approach to determine this gene's normal function. Mice 
homozygous for the disruption die before embryonic day 
8.5, indicating that the gene product has some vital cellular 
function. In one model, animals heterozygous for the dis- 
ruption may express a 20 kDa truncated N-terminal protein 
from the allele with the knockout as well as one copy of 
the normal allele (Nasir et al., 1995) and appear normal 
with no overt nervous system dysfunction. However, on 
specific behavioral tests they show abnormalities of cogni- 
tion and motor activity similar to those shown by animals 
with lesions of the striatum. In addition, quantitative analy- 
sis of two of the animals suggests decreased size of the 
subthalamic nucleus and fewer neurons in the globus pal- 
lidus. If not due to strain differences, these results would 
suggest that the HD gene is important for development 
or maintenance of the structure of the basal ganglia. Previ- 
ous magnetic resonance imaging studies of the basal gan- 
glia in presymptomatic humans with the HD expansion 
have indicated decreased volumes (Aylward et al., 1994). 
The other knockout model, which does not express the 
20 kDa N-terminal truncated protein, appears to show no 
abnormalities in the heterozygous animals (Duyao et al., 
1995). 
Several considerations uggest that the pathogenesis 
of these diseases involves a gain of function. Most of the 
disorders have dominant inheritance, which is usually as- 
sociated with gain of function. Patients with loss of a single 
allele of the HD gene do not appear to have progressive 
loss of neurons (Ambrose et al., 1994). Patients with SBMA 
show some signs of loss of androgen receptor activity; 
androgen receptors with expanded glutamine repeats 
have decreased activity (Kazemi-Esfarjani et al., 1995). 
However, SBMA cannot be due simply to loss of functional 
receptor. Patients with deletions of the androgen receptor, 
or point mutations that inactivate it, have a different pheno- 
type--that of pure androgen insensitivity. The dissimilarity 
between effects of loss of function of the relevant genes 
in HD and SBMA and the neuronal degeneration of the 
diseases argues against a dominant negative model. Fi- 
nally, in all the disorders studied so far (HD, SCA1, and 
DRPLA), the allele with the expanded repeat is present 
in mRNA and protein in brains of patients with the disease 
(Persichetti et al., 1995; Servadio et al., 1995; Sharp et 
al., 1995; Trottier et al., 1995; Yazawa et al., 1995). 
A transgenic animal model related to SCA1 has recently 
been developed (Burright et al., 1995). The human SCA1 
cDNA with an expanded repeat was inserted into the 
mouse genome under the control of a Purkinje cell-spe- 
cific promoter, yielding very high expression specifically 
in Purkinje cells of the cerebellum. Transgenic animals 
from five of six lines developed ataxia and Purkinje cell 
degeneration similar to the human disorder. Curiously, 
while the mRNA for the transgene could be detected, the 
protein expressed by the transgene could not. It is possible 
that the abnormal protein is unusually labile. It is unlikely 
that expression of the mRNA alone is responsible for the 
pathology since, in a similar experiment, animals transgenic 
for the HD gene with an expanded repeat were created in 
which the transgene inadvertently contained a frameshift 
mutation. These animals expressed mRNA but not protein 
and did not have neuronal degeneration. Thus, these data 
together appear most consistent with the hypothesis of a 
gain of function mechanism. 
Protein-Protein Interactions 
What might this gain of function be? As noted above, gluta- 
mine repeats may be involved in protein-protein interac- 
tions. There might be a stronger association with a protein 
with which the gene product normally associates. Alterna- 
tively, the gain of function might involve some novel inter- 
action. 
Several hypotheses regarding protein-protein interac- 
tions have recently been proposed. Green (1993) has sug- 
gested that proteins with expanding glutamine repeats 
might become substrates for transglutaminase activity, 
which could result in cross-linked products involving an 
s-7 glutamyl ysine isopeptide. The cross-linked proteins 
would presumably be degraded by proteolysis, but the 
residual isodipeptide could not be degraded and might 
conceivably have toxic effects within the cells. 
Another suggestion involves noncovalent protein ir, ter- 
actions. Perutz (1994; Stott et al., 1995) has suggested 
that glutamine repeats within proteins can form a "polar 
zipper" involving a 13 sheet held together by hydrogen 
bonds between the main chain and the side chain amides. 
These could form between two proteins with glutamine 
repeats or by self-bonding within one glutamine repeat- 
containing protein. Presumably, lengthening the gluta- 
mine repeat would increase the stability of the association. 
Since both of these models involve direct interactions 
of the glutamine repeats themselves, these mechanisms 
could be common for all the diseases. The differences in 
distribution of pathology might be explained by differences 
in the localization of each of the proteins to various neu- 
ronal populations. 
Other mechanisms might be specific to the gene prod- 
ucts for individual diseases and to specific cell types. For 
instance, the HD gene product with the expanded gluta- 
mine repeat present in brain appears to have altered mi- 
gration in a gel, compared with protein from nonneuronal 
cells (Schilling et al., 1995; Trottier et al., 1995). The pro- 
teins with long expanded repeats appear to migrate more 
slowly than expected, in a broad, diffuse band of lower 
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intensity than the band representing the normal allele. Re- 
gions of the brain affected in the illness, such as striatum 
and cortex, show this change more prominently than other 
regions of the brain. This could be due to an alteration of 
the protein; however, an effect due to somatic mosaicism 
(Telenius et al., 1994) also cannot be ruled out. 
Finally, it is possible that the cell type specificity of the 
pathology of each disease relates to cell type-specif ic pro- 
tein-protein interactions. For instance, a putative HAP1 
protein associates with the huntingtin protein in a gluta- 
mine repeat length-dependent manner and has brain- 
selective expression. 
Relationship to Cell Death Pathways 
Excitotoxicity has long been hypothesized to be a patho- 
genic mechanism in HD, based on the similarity of the 
pattern of cell loss in HD and in excitotoxic lesions of the 
striatum (Coyle and Puttfarcken, 1993). An elaboration on 
this model suggests that metabolically compromised neu- 
rons might be more sensitive to excitotoxicity or other 
forms of toxicity (Albin and Greenamyre, 1992; Beal, 
1992). Oxidative stress may be involved in several forms 
of cell death (Coyle and Puttfarcken, 1993), either as a 
pathogenic mechanism or as a signaling pathway to acti- 
vate other cell death pathways. Finally, neurons may die 
via apoptosis or programmed cell death, which might acti- 
vate a genetic program involved in the normal death of 
certain neurons during development. 
Different neurons in the brain appear to have different 
thresholds for various cell death mechanisms. Thus, part 
of the selective vulnerability of neurons in the brain might 
reflect intrinsic vulnerability. The results of the SCA1 
transgenic model experiments suggest that cell-autono- 
mous mechanisms can be sufficient, though pathways in- 
volving cell-cell interactions have also been hypothesized 
(Burright et al., 1995; Sharp et al., 1995; Trottier et al., 
1995). Unraveling the pathogenesis of these diseases will 
provide opportunities to explore pathways leading to neu- 
ronal cell death as the issues move from genetics to bio- 
chemistry and neuronal cell biology. 
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